8 Truths About GLP-1 Medications Almost Nobody Explains Clearly

GLP-1 medications went from a niche diabetes treatment to one of the most talked-about categories in medicine in under five years. The conversation, though, is mostly noise — recycled myths, outdated fears, and confident claims that don't hold up against the actual clinical evidence.

Here are 8 things worth knowing before this comes up in your next consultation.

1. They're Not One Drug — And the Differences Actually Matter

"GLP-1" isn't a single medication — it's a category. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the two most discussed, but they're not interchangeable. Tirzepatide targets two hormone receptors (GLP-1 and GIP) instead of one, and head-to-head research consistently shows it produces greater average weight loss than semaglutide alone — the specific medication matters, not just the category.

2. A Meaningful Portion of the Weight Lost Is Muscle — This Is the Part Most People Miss

This is one of the most under-discussed realities: in the semaglutide (Wegovy) clinical trial, roughly 40% of the weight lost came from muscle rather than fat. Tirzepatide (Zepbound) trials showed a lower but still notable share, closer to a quarter. This is precisely why resistance training and adequate protein intake aren't optional extras alongside these medications — they're what determines whether the weight lost is mostly fat or mostly the muscle you actually want to keep.

3. Not Everyone Qualifies — And That's Not Gatekeeping, It's Clinical Criteria

These medications aren't approved for casual or cosmetic use. Standard eligibility for weight-management use requires a BMI of 30+, or 27+ combined with a weight-related health condition. A doctor isn't being difficult by declining to prescribe outside these guidelines — they're following the actual clinical framework these drugs were approved under.

4. Compounded Versions Are Being Phased Out — Not Because of a Trend, But Regulation

Compounded semaglutide and tirzepatide became widely available during a genuine supply shortage starting in 2022. That shortage is officially over — the FDA declared the tirzepatide shortage resolved in December 2024 and semaglutide's in February 2025. As of April 2026, regulators have gone further, formally moving to permanently exclude these compounds from bulk compounding altogether. If a source is still offering "compounded" versions, that's increasingly a regulatory red flag, not a cost-saving option.

5. The Injection Itself Isn't the Hard Part

A common hesitation before starting is fear of the injection itself. In practice, these are subcutaneous injections with very fine needles — most patients report them as significantly less uncomfortable than a standard vaccine or flu shot, since they don't go into muscle tissue.

6. The Acne Myth Has Been Debunked

Anecdotal reports linking GLP-1 medications to acne circulated widely — but a meta-analysis covering 45 studies and 6 different GLP-1 medications, including semaglutide, found no actual link between the medication and acne.

7. These Medications Do More Than Manage Weight

Weight loss is the headline use, but some GLP-1 medications now carry approvals extending into cardiovascular risk reduction and sleep apnea — reflecting a broader physiological effect than most people associate with the category. This is part of why they're increasingly treated as chronic disease management tools, not simply appetite suppressants.

8. Stopping Cold Without a Plan Is the Most Common Mistake

These medications work by mimicking a hormone your body naturally produces — when stopped, that mimicked effect fades, and appetite regulation typically returns toward baseline. Coming off a GLP-1 without a transition plan (nutrition strategy, activity levels, sometimes a tapering approach) is one of the most common reasons people see weight regain and assume the medication "failed," when the actual issue was stopping without a plan.

The Real Takeaway

GLP-1 medications are genuinely effective, well-studied tools — not a shortcut, and not a scandal either. The real risk isn't the medication itself, it's using it without medical supervision, without a muscle-preservation strategy, or without a plan for what happens after.

This is exactly the approach behind our Body Composition & Weight Management programme — doctor-supervised, prescription-based, and built around your actual bloodwork and health profile rather than a generic protocol.

Book a consultation here if you want an honest assessment of whether this is the right fit for you.

This article is for general educational purposes and does not constitute medical advice. GLP-1 medications are prescription drugs that require medical evaluation and supervision. Individual results vary. Individual treatment plans should always be discussed with a qualified physician.